Walbert Timothy P

About Walbert Timothy P

Timothy P. Walbert is a veteran U.S. biopharmaceutical executive best known for his leadership at Horizon Therapeutics Public Limited Company, where he served as Chairman, President, and Chief Executive Officer. Public company disclosures and company biographies indicate that he founded Horizon Therapeutics and led the organization from its early growth phase through its acquisition by Amgen in 2023. His career is closely associated with building and scaling a specialty pharmaceutical company focused on rare diseases, with an emphasis on innovation, commercialization, and long-term strategic execution. Before Horizon, Walbert served as President and Chief Executive Officer of IDM Pharma, a public biopharmaceutical company that was acquired by Takeda in 2009. Earlier in his career, he held leadership roles at NeoPharm and Abbott, now AbbVie. Public sources also note that he spent time across several major pharmaceutical organizations, including Pharmacia, Merck, Pfizer, and Wyeth Ayerst. That background suggests deep experience in commercial leadership, product development, and global pharmaceutical operations, particularly in regulated markets where launch discipline and cross-functional execution matter. Walbert’s professional reputation has been built around specialty medicines, rare disease strategy, and patient-centered growth. At Horizon, he oversaw the company’s evolution into a recognized rare-disease-focused biopharmaceutical platform and guided a period of significant corporate expansion. Public announcements and board biographies also show that he has served on multiple industry and company boards, underscoring his broader governance experience and his standing within the U.S. life sciences ecosystem. A notable part of his career narrative is his commercial leadership background. Sources describe him as having led the global development and launch of HUMIRA across multiple indications during his time at Abbott, which is a significant indicator of experience in large-scale product strategy and execution. He has also been recognized for leadership in organizations connected to biotechnology, pharmaceuticals, and patient advocacy, reflecting a profile that extends beyond one company and into the wider industry. For SEO and corporate biography purposes, Walbert can be accurately framed as a former top executive of Horizon Therapeutics with extensive experience in biotech leadership, rare disease commercialization, pharmaceutical development, and board governance. His career includes leading public biopharma companies, supporting major product launches, and contributing to the growth of organizations serving unmet medical needs in the United States and globally.